Abstract
Introduction
Osteoarthritis (OA) is the commonest form of arthritic disease, characterized by articular cartilage degradation with an accompanying peri-articular b o n e r e s p o n s e [ 1 , 2 ] . O A a f f e c t s n e a r l y 2 1 m i l l i o n p e o p l e i n t h e U S A , a c c o u n t i n g f o r 2 5 % o f v i s i t s t o primary care physicians. It is estimated that 80% of the population will have radiographic evidence of OA by age 65 years, although only 60% of those will be symptomatic [3] . Clinical manifestations of OA of the knee include pain in and around the joint, stiffness of the joint, crepitation on motion and limited joint motion, among others [4] . Current recommendations for managing OA focus on relieving pain and stiffness and improving physical function as important goals of therapy [5, 6] . Currently available medication regimens for most cases include nonopioid analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) including cyclo-oxygenase II inhibitors. These pharmaceutical agents can reduce both pain and inflammation quite e f f e c t i v e l y , b u t l o n g t e r m u s e o f N S A I D s h a s b e e n found to associate with enhanced risk for gastrointestinal bleeding, hypertension, congestive heart failure and renal insufficiency, among other adverse effects [7] [8] [9] . Because of the high incidence of adverse events associated with both nonselective and cyclo-oxygenase II selective NSAID therapy, effective and safer alternative treatments for OA are urgently needed. In recent years, the gum resin extracted from the ancient herb, Boswellia serrata has gained lot of attention as a potent anti-inflammatory, anti-arthritic and analgesic agent [10, 11] . 3-O-acetyl-11-keto-betaboswellic acid (AKBA) is the most active component of Boswellia extract and has been demonstrated to be a potent inhibitor of 5-lipoxygenase (5-LOX), a key enzyme in the biosynthesis of leukotrienes from arachidonic acid in the cellular inflammatory cascade [12, 13] . 5-Loxin ® is a novel B. serrata extract enriched to 30% AKBA (US Patent publication no.: 2004/0073060A1). Affimatrix gene chip analysis demonstrated that 5-Loxin ® can potently inhibit tumor necrosis factor α (TNFα) induced gene expression of matrix metalloproteinases (MMPs), adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1); and mediators of apoptosis in human microvascular endothelial cells [14, 15] . Cell based in vitro studies suggest that 5-Loxin ® can inhibit pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin-1 β [ 1 6 ] . I n t h e c a r r a g e enan-induced inflammation model, 5-Loxin ® treatment yielded significant improvement in paw inflammation in albino Wistar rats. 5-Loxin ® also exhibited significant Anti-arhtritic efficacy in FCA induced model of Sprague-Dawley rats [14, 15] . Extensive acute and dose dependent subchronic safety studies on rats demonstrated that 5-Loxin ® is safe even at dose levels 2,000 to 3,000 times higher than the human equivalence dose [17] . In addition, 5-Loxin ® was found to be n o n g e n o t o x i c a s p e r t h e s t a n d a r d A M E S b a c t e r i a l reverse mutation assay, chromosomal aberration test in Chinese hamster cells and mouse peripheral blood micronucleus assay [18] [19] [20] [21] The efficacy and tolerabili t y o f 5 -Loxin® was assessed in a previous double blind placebo controlled clinical study. The supplementation of 5-Loxin ® was well tolerated and its efficacy against osteoarthritis was found to be statistically significant. The dose dependent efficacy of 5-Loxin ® was assessed against pain, joint stiffness, mobility and a cartilage degrading enzyme MMP-3 in OA subjects [22] . Aflapin ® is a novel synergistic composition derived from Boswellia serrata gum resin (Indian Patent Application No. 2229/CHE/2008). Interestingly it was found that the oral bioavailability of AKBA from Aflapin ® w a s b e t t e r c o m p a r e d t o t h a t o f 5 -Loxin ® . Aflapin exhibited better 5-lipoxygenase inhibitory activity and MMP-3 inhibition. Various in vitro and In vivo studies were performed to compare efficacy of Aflapin and 5-Loxin ® . These studies proved Aflapin t o b e m o r e e f f i c a c i o u s c o m p a r e d t o 5 -Loxin ® (to be presented in a separate communication). The broad spectrum safety of Aflapin was tested using a battery o f s a f e t y s t u d i e s c o n d u c t e d a c c o r d i n g t o O E C D guidelines and it was found to be safe [23] . Although a significant number of clinical study reports support the anti-inflammatory and anti-arthritic properties of Boswellia extract [24] [25] [26] [27] , no human clinical studies were done to prove the efficacy and tolerability of Aflapin in osteoarthritis. Hence in the present clinical study we sought to evaluate the comparative efficacy and tolerability of 5-Loxin ® and Aflapin ® in the treatment of OA of the knee.
Materials and Methods

Study materials
BE-30 (5-Loxin

) is a novel Boswellia serrata extract standardized to contain at least 30 percent 3-O-Acetyl-11-keto-β-boswellic acid (AKBA) using a selective enrichment process (Indian patent # 205269). The process involves selective enrichment of AKBA while simultaneously suppressing the concentration of triterpene compounds that are less active and those that antagonize the activity of AKBA. Aflapin is a novel synergistic composition containing B. serrata extract selectively enriched with AKBA and B. serrata non-volatile oil. The non-volatile oil was prepared using a special process (PCT application # PCT/IN2009/000505) involving selective removal of Boswellic acids followed by removing volatiles under high vacuum. The composition was standardized to contain at least 20% AKBA.
Study design
This trial was performed at Alluri Sitarama Raju Academy of Medical Sciences (ASRAM), Eluru, Andhra Pradesh, India from July 2008 to December 2008 (clinical trial registration number: ISRCTN80793440). The study protocol was evaluated and approved by the ASRAM Institutional Review Board (IRB). An overview of the clinical study is provided in Figure 1 . Briefly, 186 subjects out of 283 attending the orthopaedic outpatient department of the ASRAM hospital were selected in the first phase of the s c r e e n i n g p r o c e d u r e , b a s e d o n t h e s i g n s , s y m p t o m s and radiological changes consistent with OA. A total of 60 subjects suffering for more than 3 months with medial tibio-femoral OA were selected using inclusion/exclusion criteria summarized in Table 1 . All subjects signed the IRB approved consent form. Subjects, who were otherwise healthy, were aged 40 years o r o l d e r a n d h a d a d i a g n o s i s o f O A , f u l f i l l i n g t h e American College of Rheumatology classification crit e r i a [ 4 ] . A f t e r r e c r u i t m e n t , t h e s u b j e c t s w e r e r a nd o m l y d i s t r i b u t e d i n t o t h r e e g r o u p s . T h e d e m ographic data and baseline characteristics are summarized in Table 2 . Before study enrollment, subjects were required to be taking an NSAID at prescription strength for at least 30 days or acetaminophen 1,200 to 4,000 mg/day on a regular basis (at least 25 of the preceding 30 days) with a history of therapeutic benefit. Eligibility requires subjects to meet specific flare criteria upon medication washout. At screening, subjects had to d e m o n s t r a t e a v i s u a l a n a l o g s c a l e ( V A S ) s c o r e b etween 40 and 70 mm during the most painful knee movement, and Lequesne's Functional Index (LFI) score greater than 7 points after 7-day withdrawal of usual medication.
A total of 60 selected subjects with symptoms of moderate to mild OA were recruited into the study. Each s ub ject w as r andom l y as sign ed t o a t reat m en t group using a randomization table generated using v a l i d a t e d c o m p u t e r s o f t w a r e C O D E ; I D V , G a u t i n g , Germany. The clinical trial pharmacist and statistician ensured that treatment codes remained confidential. The subjects were distributed into three groups: placebo (n=20); 5-L o x i n ® g r o u p , i n w h i c h s u b j e c t s r eceived 50 mg encapsulated 5-Loxin ® twice daily (n=20); and Aflapin group, in which subjects received 50 mg encapsulated Aflapin ® twice daily (n=20). Subjects in the placebo group received two capsules of similar color, taste and appearance but filled with suitable exicipient. Each subject completed a questionnaire, providing details regarding demographics, medical history and nutritional status, at the baseline evaluation and during the follow-up evaluations on days 7, 30, 60 and 90. At the baseline evaluation, and at each visit during the 90-day follow up period, all subjects were assessed for pain and physical function using validated pain scores. Various parameters of serum biochemistry, hematology and urine analysis were carried out on each evaluation day. Safety was monitored by clinical and laboratory assessments conducted during the study visits and subject-reported adverse experiences.
Functional disability and pain score evaluation
Functional disability was assessed by the investigators at baseline and on each follow-up visit (days 7, 30, 60 and 90). Questionnaire-based assessment of pain, stiffness and physical function were done using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) index [28] , LFI [29] and VAS [30] . The WOMAC index produces scores for three subscales: pain, stiffness and physical function. T h e p a i n , s t i f f n e s s a n d f u n c t i o n s u b s c a l e s o f t h e WOMAC were normalized to a scale of 0 to 100 units (NU) [31] . The pain subscale was the average of the first five questions of WOMAC and measured using the NU scale from 0 ('no pain') to 100 ('extreme pain') for each question. The stiffness subscale was the average of questions 6 and 7, measured using the NU scale from 0 ('no stiffness') to 100 ('extreme stiffness') for each question. The physical function subscale was the average of questions 8 through 24 of the WOMAC and measured by NU scale from 0 ('no difficulty') to 100 ('extreme difficulty') for each question. Analyses of these end-points were based upon the time-weighted average change from baseline over 90 days.
Hematological and biochemical evaluations
For assessment of safety of 5-Loxin ® and Aflapin ® , several parameters were evaluated in serum, urine and whole blood of all subjects at each visit of t h e s t u d y d u r a t i o n . S e r u m b i o c h e m i c a l p a r a m e t e r s and hematological parameters were measured using an automated analyzer (HumaStar 300) and a hematological counter (Humacount, Human, Wiesbaden, Germany). The urine analysis was carried out using UroColor™10 Dip Sticks and Urometer 600 (Standard Diagnostics, Kyonggi-do, Korea) and by sediment analysis using microscopy.
In vitro studies to identify mechanisms of actions of Aflapin: Effect on expression of ICAM-1 and MMP3
Adhesion molecule (ICAM-1) expression on endothelial cells: 20,000 Endothelial cell (HDMEC, Lonza Inc., USA) per well in quadruplicate wells were treated with medium, vehicle, TNFα (20ng/ml), TNFα (20ng/ml) with 5-Loxin ® or Aflapin ® (4µg/ml each) for 24 hour then ICAM-1 ELISA was performed o n f i x e d c e l l s o f t h e s e w e l l s a s p e r o u r e s t a b l i s h e d protocol [32] .
Effect on secretion of MMP3 in TNFα induced human chondrocyte: Human primary Chondrocytes (HCH) was procured from Promo Cell GmbH (Heidelberg, Germany). HCH cells were cultivated in the growth medium (Ready-
Rescue medication
Subjects were prescribed ibuprofen 400 mg tablets (maximum 400 mg thrice daily; total 1,200 mg) as rescue analgesia during the study based on pain intensity reported to the study physician by the patient. However, the subjects were instructed not to take medicine at least 3 days before each evaluation. No other pain relieving interventions were allowed during the study period.
Statistical analysis
Detailed statistical analyses were performed using SAS software to evaluate the efficacy of 5-Loxin ® and Aflapin ® in comparison with the placebo group in terms of improvement in pain and physical function scores at baseline and on days 7, 30, 60 and 90 of treatment and serum MMP-3 levels at baseline and on d a y 9 0 o f t r e a t m e n t . P a i r -w i s e c h a n g e s w e r e e xamined by carrying out a least significant difference test for all possible pairs. The significance of the effects of the treatment groups was compared by using one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. Results with P<0.05 are considered statistically significant. This is a three-arm (5-Loxin ® , Aflapin ® and placebo), randomized, double-blind, placebo-controlled, single-centre trial conducted over 90 days. The trial's primary objective was to determine the effects of 5-Loxin ® and Aflapin ® on pain, physical function and joint stiffness. For power calculations, the estimates for variability and assumed mean changes for each treatment group w e r e b a s e d o n r e s u l t s f r o m p r e v i o u s p l a c ebo-controlled studies of celecoxib, etoricoxib and rofecoxib conducted in subje c t s w i t h O A [ 3 3 -36] . We believe that an intervention that gives an average improvement of mean change ± 1 standard deviation, rather than mean change alone will provide results of greater significance [37] . Our trial is designed to have more than 80% power to detect a situation in which either active drug dosage yields an improvement to at least mean change ± 0.9 standard deviation, under a conservative assumption, and we tested differences between groups in mean improvement using ANOVA (α=0.05, two-sided). W i t h 2 0 s u b j e c t s p e r group, we would have a 93% chance of observing at least one example of any side effect occurring in 10% or more of the patient population at a specific dosage.
Results
Baseline characteristics
Descriptive statistics comparing demographic variables, baseline disease characteristics and baseline outcome measures (LFI, VAS, WOMAC pain, function and stiffness sub-s c o r e s ) a r e p r o v i d e d i n T a b l e 2 . Overall, the treatment groups receiving 5-Loxin ® 100 mg/day, n=19, Aflapin ® 100 mg/day, n=19 and placebo n=19, were similar with respect to age, Body Mass Index and pain severity ( Table 2 ). The subjects were randomly distributed into three groups.
Clinical efficacy
We compared the scores between the treatment groups obtained at day 90. Both the treatments with 5-Loxin ® and Aflapin ® conferred clinically and statistically significant improvements in pain scores and physical ability scores in OA subjects between baseline and day 90 (Table 3 ). Tukey's multiple comparison test revealed statistically significant improvements by 31.6% (P=0.006), 30.3% (P=0.009) and 42.2% (p=0.006) in VAS, WOMAC pain, and WOMAC stiffness scores, respectively, in the 100 mg 5-Loxin ® treated group in comparison with the placebo group (Table 3) . Improvements by 18.35% (P=0.060) and 21.25% (P=0.078) in LFI and WOMAC functional ability scores, respectively were also achieved in the 5-Loxin ® g r o u p ( T a b l e 3 ) . I n c o m p a r i s o n w i t h t h e placebo group, the Aflapin ® 100 mg treated group also exhibited statistically significant improvements in all parameters tested (Table 3 ). The Aflapin group showed improvements by 47.3% (P<0.0001), 35 .8% (P=0.0004), 61.7% (P<0.0001), 60.1% (P=0.0001) and 49.4% (P=0.0001) in VAS, LFI, WOMAC pain, WOMAC stiffness and WOMAC functional ability scores, respectively. It is worth noting that both 5-Loxin ® and Aflapin ® treatment groups exhibited improvement in pain scores and physical ability scores as early as 7 days after the start of treatment, and these indices continued to improve throughout the 90 days of treatment (Figure 2) . After 7 days, the 5-Loxin ® treatment group exhibited 8.09% (P=0.002), 8.68% (P=0.031) and 8.35% (p=0.015) reductions in VAS, WOMAC pain and WOMAC function respectively, compared with the corresponding baseline scores. After 7 days, the Aflapin treatment group exhibited 12.8% (P=0.0004), 9.17% (P=0.003), 11.78% (P=0.012), 18.48% (P=0.012) and 10.24% (p=0.005) reductions in VAS, LFI WOMAC pain, WOMAC stiffness and WOMAC function scores respectively, compared to the corresponding baseline scores (Figure 2 ). In comparison with corresponding baseline data, the change in scores in the treatment groups was tested for significance using Tukey's multiple comparison test; * p<0.05; ** p<0.005.
Table 3: Student's t-t e s t ( p a i r e d ) a n a l y s e s f o r c o m p a r i s o n o f t h e s c o r e s o b t a i n e d f r o m t h e A f l a p i n a n d 5 -Loxin groups at day 90
Aflapin inhibits secretion of MMP-3 in TNFα-induced human primary chondrocytes
In OA, the loss of collagen from articular cartilage is proportional to the disease severity (38). Under the influence of pro-inflammatory cytokines, increased production and secretion of collagenases such as MMP-3, MMP-13 is the crucial event for enhanced collagen degradation in OA [39] . Therefore, we sought to evaluate whether 5-Loxin and Aflapin can modulate MMP-3 secretion in TNFα, a p o t e n t p r oinflammatory cytokine induced human primary chondrocytes. Figure 3 shows a steep increase in MMP-3 secretion in TNFα-induced chondrocytes and dose-dependent inhibition of MMP-3 secretion in 5-Loxin and Aflapin treated cultures. Interestingly, we observed, Aflapin (IC 50 at 18.5 µg/ml) provided (41.36%) better efficacy than 5-Loxin (IC 50 at 31.71 µg/ml) in inhibiting MMP-3 secretion from TNFα-induced human chondrocytes.
Aflapin inhibits ICAM-1 expression in activated endothelial cells
OA is a degenerative joint disorder. However, t h e r e a r e m i g r a t i o n s o f i n f l a m m a t o r y c e l l s i n t h e synovial fluid. Adhesion molecule expression on endothelial cells helps in the diapedesis of these cells. Therefore, in order to determine whether 5-Loxin ® and Aflapin ® treatments can ameliorate the ICAM-1 expression, we evaluated the ICAM levels on HDMEC. Figure 4 depicts that 5-Loxin ® and Aflapin ® significantly reduce TNFα induced ICAM-1 express i o n ( p < 0 . 0 1 , s t u d e n t t -test). Interestingly, Aflapin ® shows more capability to reduce ICAM-1 secretion than that of 5-Loxin ® .
Biochemical evaluations
As a part of the safety evaluation, laboratory tests were performed to evaluate different biochemical parameters (serum and urine) and hematological parameters. The significance of the differences between baseline and 90 days was tested by using repeated measures ANOVA. The f ratio is considered significant if P<0.05. Although minor changes were observed in some of the parameters, they remained within the normal laboratory range. Statistical analyses of these parameters did not indicate any significant changes. Similarly, no significant changes in hematological and urinary parameters were observed in the active treatment groups when compared to the placebo (data not shown). These findings further demonstrate the safety of 5-Loxin ® and Aflapin ® in humans.
Adverse Events and Dropouts
During the course of the 90-day study, no major adverse events were reported. However, acidity was reported as a minor adverse event by two subjects during the study; one each from placebo and Aflapin supplemented groups, respectively.
Three subjects one from each placebo, 5-Loxin ® and Aflapin ® supplemented groups were dropped out from the study due to their un-availability during the entire study period. 
Discussion
This is the first clinical study to evaluate the efficacy of Aflapin ® in OA subjects. Aflapin is a novel synergistic composition comprising AKBA enriched B. serrata extract and non acidic gum extract of B. serrata. In a battery of preclinical studies designed in in vitro cellular models and in vivo animal models, Aflapin exhibited significantly better anti-inflammatory activities in comparison with 5-Loxin ® (Data to be presented in a separate communication). 5-Loxin ® is a Boswellia serrata extract standardized to 30% AKBA. Its multidirectional activities related to anti-inflammatory efficacies obtained in appropriate cellular, animal models and in human subjects have established that 5-Loxin ® is a potent dietary supplem ent for t he m ana gem en t of inf l am m at ory d ise ase s such as osteoarthritis [14-2 2 ] . I n a s e r i e s o f e xperiments designed in in vitro cellular and in vivo animal models, Aflapin showed significantly better efficacy in comparison with 5-Loxin ® . In addition, Aflapin exhibited better AKBA bioavailability than 5-Loxin ® in Wistar rat model. Broad spectrum safety of Aflapin was also established in a battery of acute and sub-acute toxicity studies in rat and rabbits. These findings altogether motivated us to evaluate efficacy of Aflapin in comparison with 5-Loxin ® against osteoarthritis in human subjects. In the present 90-day clinical study, we assessed the efficacy and tolerability of Aflapin in comparison with 5-Loxin® in OA subjects. Pain, stiffness of joints, reduced joint movement and physical disability are the major clinical manifestations of OA [1, 40, 41] . Our study demonstrates that Aflapin potentially improves pain, joint stiffness and physical function in OA subjects (Figure 2) . In order to check improvements in the treatment groups, we compared the data for all parameters between the baseline and day 90. Paired t-test revealed that both treatment groups showed statistically significant improvements in all parameters.
Compared to the placebo, 5-Loxin ® supplement a t i o n f o r 9 0 d a y s , s i g n i f i c a n t l y r e d u c e d V A S , WOMAC-pain, WOMAC-stiffness (Table 3) , which are consistent with our previous observations [22] . Whereas, Aflapin supplementation for 90 days, resulted in significant reduction in all pain scores tested in comparison with placebo. These findings suggest that Aflapin has better therapeutic efficacy against OA compared to 5-Loxin ® . We observed that, in comparison with baseline, there were downward trends in VAS score and WOMAC scores in the placebo group. We believe that this might be partly attributable to the placebo effect [42, 43] manifested while administering the questionnaires to placebo subjects and partly due to the consumption of ibuprofen as rescue medication b y m o r e s u b jects in the placebo group during the study. It is noteworthy that 5-Loxin ® possesses sign i f i c a n t e f f i c a c y i n l o w e r i n g V A S s c o r e b y 8 . 0 9 % (P=0.022), WOMAC pain score by 8.68% (0.031) and WOMAC function score by 8.35% (P<0.015) in OA s u b j e c t s a s e a r l y a s 7 days after the initiation of treatment. In comparison, Aflapin showed significant reduction in all the pain scores assessed including V A S s c o r e b y 1 2 . 8 % ( P=0.0004), LFI score by 9.17% (P=0.003), WOMAC pain score by 11.78% (P=0.012), WOMAC stiffness score by 18.48% (P=0.012) and WOMAC function score by 10.24% (P=0.005) ( Figure  2) . These findings therefore indicate that 5-Loxin ® and Aflapin ® confers prompt and significant pain relief, improvement in physical ability and quality of life in OA subjects. However, Aflapin showed better reduct i o n i n a l l t h e t e s t e d p a i n s c o r e s a n d h e n c e c a n b e considered superior to 5-Loxin ® .
Pathogenesis of osteoarthritis is a complex process. These include mechano-transduction, the interplay between metalloproteases (MMP3, MMP13), protease inhibitors and cytokines on cartilage degradation and mechanisms of cartilage repair [40, 44, 45] . MMP-3 is over-expressed in OA and cause degeneration of cartilage tissue [44, 45] . Cytokines act via autocrine and endocrine functions to alter cartilage homeostasis. Interleukin-1 (IL-1) and TNF-α are perhaps the best characterized cytokines for cartilage degradation (46, 47) . They are synthesized by chondrocytes and FLS. These cytokines act in various ways in the pathogenesis of OA such as inhibition of synthesis of type 2 (articular) cartilage and activation of catabolic metalloproteases including MMP-3 which plays a critical role in cartilage degradation [44, 45] . A role of synovitis in OA can't be disregarded either. It is a well established clinical observation that pain and swelling in OA improves for months following intra-articular corticosteroid injection. In addition, histologic studies suggest that localized inflammatory changes characterized by foci of inflammatory cells occur in up to 50% of O A p a t i e n t s [ 4 8 ] . I n t h i s s t u d y t o f i n d o u t possible mechanism of actions of Aflapin we carried out in vitro studies to evaluate whether Aflapin can inhibit metalloprotease secretion or influence the inflammatory component of osteoarthritis. We observed: (1) Aflapin inhibits TNFα induced MMP-3 secretion in chondrocytes; (2) Aflapin inhibits TNFα induced expression of ICAM-1 in endothelial cells.
Overall, the foregoing data together demonstrates the better ability of Aflapin compared with 5-Loxin® in terms of reducing the pain, improving physical function, quality of life and joint health. Presumably these improvements might occur through down regulation of cartilage degrading enzymes such as MMP-3 i n O A s u b j e c t s . T h e p r e s e n t s t u d y a l s o demonstrates no major changes in the hematological parameters, serum biochemical parameters and in urine analysis in the treatment groups compared to placebo. In addition, no major adverse effect was reported by the subjects in the treatment groups. Taken together, these observations further demonstrate that 5-Loxin ® and Aflapin ® are potentially safe in the t r e a t m e n t o f O A i n h u m a n s a n d m o r e s p e c i f i c a l l y Aflapin ® i s m o r e e f f i c a c i o u s i n t h e m a n a g e m e n t o f osteoarthritis than 5-Loxin ® .
Conclusion
I n s u m m a r y , t h e p r e s e n t s t u d y p r o vides the evidence in support of the potential efficacy and tolerability of 5-Loxin ® and Aflapin ® in subjects with OA; 5-Loxin ® and Aflapin significantly improved joint function. Aflapin exhibited better therapeutic efficacy over 5-Loxin ® at 100 mg/day; it reduces pain rapidly, as early as after 1 week of treatment. Furthermore, in vitro studies also provide evidences that compared to 5-Loxin, Aflapin is capable of inhibiting cartilage degrading enzyme MMP-3 and has the potential to regulate the inflammatory component in by inhibiting ICAM-1. Most importantly, we have observed that 5-Loxin ® and Aflapin ® are safe for human consumption, even for long term supplementation. 5-Loxin ® and Aflapin ® are promising alternative therapeutic options, that may be used as nutritional supplements for management of OA.
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